Coloma Jason V 4

4 · Maze Therapeutics, Inc. · Filed Jul 2, 2026

AI-generated summary of this filing

Updated Jul 2, 2026

Maze Therapeutics (MAZE) CEO Jason V. Coloma Sells Shares

What Happened

Jason V. Coloma, CEO of Maze Therapeutics, sold a total of 34,501 shares in three open-market transactions on July 1, 2026, generating about $1,034,253 in proceeds. The reported lots were: 30,311 shares at a weighted average price of $29.95 ($907,921), 2,593 shares at $29.98 ($77,726), and 1,597 shares at $30.44 ($48,606). All transactions are sales (S).

Key Details

Transaction date: July 1, 2026; Form 4 filed July 2, 2026 (within the typical 2-business-day window).
Reported totals: 34,501 shares sold for approximately $1,034,253.
Price details: the filing reports weighted-average prices; individual execution prices ranged roughly from $29.38 to $30.49 per share across the lots (full breakdowns available from the filer/SEC on request).
Plan / holding notes:
- At least one sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Coloma on Feb 6, 2026.
- Some of the securities sold were held directly by trusts for which Coloma and his spouse are co-trustees (The Coloma 2021 Irrevocable Trust and the Coloma Family Trust).
Shares owned after the transactions are not specified in the provided excerpt.

Context

These are open-market sales, often routine and sometimes executed under prearranged 10b5-1 plans; such sales do not by themselves indicate management’s view of the company’s prospects. The filing’s weighted-average pricing and footnotes mean the reported prices represent multiple executions across the ranges noted.

Form 4

Period: 2026-07-01

DirectorChief Executive Officer

Transactions

Sale
Common Stock
[F1][F2][F3]
2026-07-01$29.98/sh−2,593$77,726→ 23,337 total(indirect: By Trust)
Sale
Common Stock
[F1][F4][F5]
2026-07-01$29.95/sh−30,311$907,921→ 288,768 total(indirect: By Trust)
Sale
Common Stock
[F1][F6][F5]
2026-07-01$30.44/sh−1,597$48,606→ 287,171 total(indirect: By Trust)

Footnotes (6)

[F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
[F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.455 to $30.38 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4 and 6 of this Form 4.
[F3]These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust"), for which the reporting person and his spouse serve as co-trustees.
[F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.375 to $30.37 per share, inclusive.
[F5]These securities are directly held by the Coloma Family Trust (the "Family Trust"), for which the reporting person and his spouse serve as co-trustees.
[F6]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.385 to $30.49 per share, inclusive.

Signature

/s/ Courtney Phillips, as attorney-in-fact|2026-07-02

1 file